 |
L.C.
General User
Member Since: 8/31/2005
Location: United States
Post Count: 10,260
Status: Offline
|
|
|
| New studies on treatments show improvements |
|
|
Posted: 6/25/2020 11:50:05 PM |
| |
First, a study where they gave HCQ early, in reasonable dose, as soon as people tested positive, and they also monitored zinc levels:
https://www.sciencedirect.com/science/article/pii/S147789...
Average days hospitalized was reduced from 9.2 days to 7.3 days. Patient ending up in the ICU was reduced from 6.8% to .8%, and the death rate was reduced from 3.1% to 0.5%. In total, "poor clinical outcomes", as defined by death, transfer to ICU, or hospitalization for over 10 days, was reduced from 17.6% to 3.9%. In 0.67% of patients, QTc elongation was noted, and they were removed from HCQ. No deaths were reported due to HCQ.
For severe cases, Tocilizumab, which targets IL-6 receptors to block cytokine storms, works:
https://www.thelancet.com/journals/lanrhe/article/PIIS266...
Looking at severe cases, 20% died with standard care, compared to 7% who got Tocilizumab.
So does Anakinra, which blocks IL-1 receptors:
https://www.thelancet.com/journals/lanrhe/article/PIIS266...
Patients included people with severe bilateral pneumonia. Negative outcomes (admission to ICU or death) occurred in 25% of cases that received Anakinra, compare to 75% of patients on standard care. Anakinra reduced both mortality and the need for mechanical ventilation without significant side effects.
“We have two ears and one mouth so that we can listen twice as much as we speak.” ― Epictetus
|
|
|
|
